Tecentriq (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs)

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Tecentriq
Active substance
atezolizumab
Therapeutic area (MeSH)
  • Carcinoma, Transitional Cell
  • Carcinoma, Non-Small-Cell Lung
  • Urologic Neoplasms
  • Breast Neoplasms
  • Small Cell Lung Carcinoma
Procedure number
EMEA/H/C/00414/II/0054
Regulatory outcome
Variation
DHPC type
Adverse event
Human ATC code
L01XC
Dissemination date
25/03/2021

How useful was this page?

Add your rating